CN111407785A - 一种用于治疗股骨头坏死的复合脱细胞基质注射液及使用方法 - Google Patents
一种用于治疗股骨头坏死的复合脱细胞基质注射液及使用方法 Download PDFInfo
- Publication number
- CN111407785A CN111407785A CN202010293104.1A CN202010293104A CN111407785A CN 111407785 A CN111407785 A CN 111407785A CN 202010293104 A CN202010293104 A CN 202010293104A CN 111407785 A CN111407785 A CN 111407785A
- Authority
- CN
- China
- Prior art keywords
- injection
- acellular matrix
- solution
- matrix
- femoral head
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 73
- 238000002347 injection Methods 0.000 title claims abstract description 50
- 239000007924 injection Substances 0.000 title claims abstract description 50
- 230000017074 necrotic cell death Effects 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 7
- 239000002131 composite material Substances 0.000 title description 19
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 20
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 13
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 12
- 230000003071 parasitic effect Effects 0.000 claims abstract description 10
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 10
- 210000004394 hip joint Anatomy 0.000 claims abstract description 8
- 210000000588 acetabulum Anatomy 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 45
- 210000004027 cell Anatomy 0.000 claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 239000008055 phosphate buffer solution Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 15
- 241000125175 Angelica Species 0.000 claims description 13
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000005185 salting out Methods 0.000 claims description 6
- 230000003833 cell viability Effects 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 4
- 108090000284 Pepsin A Proteins 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229940111202 pepsin Drugs 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 210000001361 achilles tendon Anatomy 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 210000002391 femur head Anatomy 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 210000003516 pericardium Anatomy 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 210000004303 peritoneum Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000004876 tela submucosa Anatomy 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 abstract description 7
- 230000004069 differentiation Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 5
- 239000008279 sol Substances 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 210000000963 osteoblast Anatomy 0.000 abstract description 3
- 230000000472 traumatic effect Effects 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000003467 diminishing effect Effects 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000014066 European mistletoe Nutrition 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 2
- 241000221012 Viscum Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010023215 Joint effusion Diseases 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical group O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3637—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the origin of the biological material other than human or animal, e.g. plant extracts, algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/365—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3847—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
Abstract
本发明公开了一种复合脱细胞基质注射液，所述复合脱细胞基质注射液作为股骨头坏死修复材料用于临床治疗。所述复合脱细胞基质注射液由生物脱细胞基质溶胶、骨髓间充质干细胞及当归寄生液复合而成，于术中注入股骨头与髋臼之间髋关节部位，可提供组织修复的微环境，促进骨髓间充质干细胞增殖分化为成骨细胞，诱导新生血管形成及新骨形成，并具有消炎镇痛的作用，可用于早中期非创伤性股骨头坏死的治疗。
Description
技术领域
本发明涉及一种复合脱细胞基质注射液的制法及其在股骨头坏死中的治疗应用，属于医用生物材料领域、组织工程修复领域。
背景技术
非创伤性股骨头坏死的致病因素主要分为两种：慢性酒精中毒、滥用激素类药物。酒精及激素使股骨头周围血液循环发生障碍，引起供血不足，从而使股骨头坏死、骨小梁断裂、股骨头塌陷，严重时可导致患者瘫痪。股骨头坏死分为四个时期: 
、
期为塌陷前期；
期为股骨头塌陷期，
期为股骨头塌陷发展至关节炎，在早、中期发现尚可治疗，发展至晚期则需开展人工髋关节置换术，给患者造成极大痛苦。
细胞外基质是由细胞合成分泌至细胞膜外、分布在细胞表面或之间的大分子，主要成分包括胶原蛋白、糖蛋白、黏蛋白等，其他成分有多糖（透明质酸、硫酸软骨素）、脂质及生长因子等。这些活性物质构成复杂的网络结构，在细胞增殖、分化、迁移和血管生成方面有着重要的作用。脱细胞基质液在体内可形成组织修复支架，充当细胞外基质，提供有利于干细胞生长分化的微环境，促进血管生成。
骨髓间充质干细胞（BMSCs）是未分化多潜能干细胞，在组织再生领域具有巨大应用潜力。BMSCs可分化为成骨细胞、软骨细胞、成肌细胞、脂肪细胞、成纤维细胞，同时也可介导骨矿化及新生血管生成。这些功能预示了BMSCs在治疗早中期股骨头坏死的应用前景。BMSCs具有免疫原性低，多向分化功能，易于分离、扩增，来源广泛等优点，在股骨头坏死治疗中应用越来越多。BMSCs单独植入治疗股骨头坏死虽然可以减轻症状，但由于缺乏良好的骨架材料，细胞存活时间短，治疗效果不显著。
当归寄生液具有抗氧化、抑制血栓形成、降低血液黏滞度的作用，具有增强免疫功能、加强巨噬细胞吞噬能力的作用，有明显的抗炎、抗渗出、抗增生作用。其成份为当归和槲寄生。其中，当归为血中之圣药，具有补血活血、化瘀止痛、生肌健骨的功效，现代药理研究已证明，有抗炎、清除氧自由基、保肝护肾、增强免疫功能等作用。槲寄生具益肝肾、强筋骨、祛风湿、通经络益血之功效。现代药理研究其能扩张血管、镇静中枢，同时有减少关节积液、改善关节骨端变性及骨质疏松状态、增宽狭窄的关节间隙等作用。
脱细胞基质液与BMSCs、当归寄生液按比例混合后，基质液将BMSCs及当归多糖包裹在内，其所含生长因子可诱导BMSCs分化再生，诱导BMSCs分化为骨组织，混合的基质液在体内可形成缓释体系，延长BMSCs的作用时间，也还可防止细胞随骨内压增加而流失，还具有促进新生血管形成的作用，血管生成和骨生成之间关系十分密切，在骨损伤修复中新生血管形成被视为重要因素之一。
专利（CN201910178248.X）公开了一种用于腔隙注射治疗缺血性股骨头坏死的人源脐带间充质干细胞注射液的制备方法，该注射液的软骨分化诱导剂包括葡萄糖异黄酮、骨形成蛋白-2、抗坏血酸、地塞米松、β-甘油磷酸钠，该类诱导剂不能固定间充质干细胞，无法提供再生微环境，干细胞在体内易流失。专利（CN201010152461.2）公开了一种治疗骨损伤细胞注射剂及其制备方法，该凝胶主要为泊洛沙姆凝胶，属于高分子聚合物，不利于肾脏排泄。
目前还未有脱细胞基质液、骨髓间充质干细胞及当归寄生液复合再生材料，构建组织修复微环境，用于股骨头坏死组织修复的相关报道。
发明内容
本发明提供了一种用于治疗股骨头坏死的复合脱细胞基质注射液及使用方法，通过将哺乳动物组织细胞外基质进行脱细胞处理和基质液化处理，制备出脱细胞基质液，消除了异种组织的免疫原性，保留细胞外基质活性成分，成为干细胞安全载体，并能够诱导干细胞分化及组织再生。BMSCs从骨髓中提取培养，当归寄生液为生产检验合格的市售产品，将脱细胞基质液与骨髓间充质干细胞的细胞液及当归寄生液混合摇匀后，注射于髋关节股骨窝关节腔内，该复合材料具有良好的治疗效果及安全性。
为了实现上述发明目的，本发明提供以下技术方案：
一种用于治疗股骨头坏死的复合脱细胞基质注射液，其特征在于，所述复合脱细胞基质注射液由异种哺乳动物组织经脱细胞处理得到的基质溶胶、骨髓间充质干细胞及当归寄生液复合而成，所述复合脱细胞基质注射液中组成成分的体积份为脱细胞基质溶胶0.8-1.2份、骨髓间充质干细胞液（细胞密度1×106～107个/ml，细胞活率>90%）0.8-1.2份和当归寄生注射液0.8-1.2份。
一种脱细胞基质液的制备方法，包括以下步骤：
（1）首先用PBS对动物组织进行清洗等预处理，经病毒灭活后粉碎；
（2）加入10%的氯化钠溶液浸泡摇床震荡处理2h，30℃/200rpm；
（3）过滤，将组织用纯化水清洗3次，30min/次，摇床震荡处理10min，30℃/200rpm；
（4）用3%碳酸钠溶液浸泡3小时脱脂，纯化水洗3次：10min/次，30℃/200rpm；
（5）用4%胰蛋白酶浸泡摇床3小时，纯化水洗3次：10min/次，30℃/200rpm；
（6）再经核酸酶降解细胞中核酸成分，充分清洗以除去去垢剂后得到脱细胞基质，经冻干后得到脱细胞基质粉；
（7）配制pH=2 HCl溶液、10×PBS溶液、1×PBS溶液、0.1mol/L NaOH溶液；
（8）按照1g基质粉/100ml HCl溶液/0.1g胃蛋白酶的比例进行酶解，酶解条件：200rpm/min、30℃、36h；
（9）36h后酶解液中加入按1g基质液/0.05g胃蛋白酶的比例进行二次酶解，酶解条件：200rpm/min、30℃、36h；
（10）过滤，除去未酶解基质；
（11）酶提取液中加入氯化钠固体颗粒至浓度为 4mol/L，4℃下盐析 36 h；
（12）盐析后过滤分离，沉淀用5倍量的3%的醋酸溶液溶解，然后再次盐析，纯化水冲洗沉淀数次，冻干；
（13）按照1g冻干粉/100ml pH=2 HCl溶液的比例将冻干粉进行复溶；
（14）按照12ml基质溶液加1.3ml 10×PBS加1.2ml 0.1mol/L NaOH溶液加5.5ml 1×PBS的比例在低温下混合，调节pH pH=7.3～7.5；
（15）过滤除菌后装入无菌注射器中，2-8℃低温保存。
骨髓间充质干细胞的提取及培养方法：
（1）BMSCs提取过程在层流无菌手术室进行，对患者进行局部麻醉后，选取患者双侧髂后上棘部位进行穿刺，用含有肝素抗凝液的注射器抽取骨髓血，将抽取的骨髓血打入医用无菌采血袋中；
（2）在无菌条件下，将采集袋中的自体骨髓血装入50ml离心管中，在2000r/min的转速下离心20min；
（3）离心完成后，去除离心管上层血浆，再用生理盐水稀释至30ml，并混合摇匀；
（4）将分离稀释后的骨髓细胞与20mlFicoll分离液，混合摇匀，1800r/min的转速下离心20min；
（5）离心后，用移液器小心吸取上层血浆与Ficoll分离液之间的白膜层细胞，用30ml生理盐水稀释吸取液，混合摇匀，1600r/min的转速下离心14min；
（6）离心后，用移液器吸取底部细胞，放入新的离心管中，加30ml生理盐水稀释，混合摇匀，1400r/min的转速下离心12min；
（7）再次吸取底部细胞，加30ml生理盐水稀释，混合摇匀，1200r/min的转速下离心10min；
（8）收取细胞加入无血清培养基，37℃，5%CO2条件下培养扩增至第3-5代使用。
一种复合脱细胞基质注射液的制备方法：
收集第3-5代BMSCs，按照0.8-1.2份脱细胞基质液、0.8-1.2份骨髓干细胞、0.8-1.2份当归寄生液的比例混合，细胞密度1×106～107个/ml（活率>90%），形成复合修复材料，以上制备全过程均在无菌环境中进行。
治疗方法：
患者患侧在上，侧膝卧位，术者对患侧髋部用碘付常规消毒3遍，采用10ml注射器用12cm注射针头，将复合脱细胞基质注射液混合摇匀，注射于患侧股骨关节腔内，股骨头与髋臼之间髋关节部位。注射液复温条件为25℃-37℃，1-2min，复温后需在3min内完全注射入体内。
本发明所述的复合脱细胞基质注射液中脱细胞基质液、骨髓间充质干细胞液和当归寄生注射液成分最优化体积比为，脱细胞基质液1.2份，骨髓间充质干细胞液1份，当归寄生注射液0.8份。
与现有发明相比，本发明具有以下优点：
（1）脱细胞基质液于25℃-37℃左右条件下，随着时间增加，体系粘弹性增加，转化为半流动态，从纯粘性液体转变成粘弹性水凝胶，在体内可形成组织修复支架，充当细胞外基质，提供有利于干细胞生长分化的微环境，促进血管生成，为股骨头再生提供生物支架及营养成分，其所含生长因子可诱导BMSCs分化再生，在体内可形成缓释体系，延长BMSCs的作用时间，有效提高细胞的存活率，材料本身可进行生物降解，可随人体代谢吸收排泄；
（2）本发明制得的脱细胞基质液制备过程中，采用的试剂温和，有效保留细胞外基质中活性结构蛋白、多糖及生长因子，可特异性引导骨组织的再生修复。所制备材料可扩张血管、促进血管化形成，以及消炎镇痛作用；
（3）本发明提供的治疗材料与方法无毒副作用、能加快全愈时间解除患者痛苦，通过股骨关节腔注射的方式可避免开创手术的风险，能促进早中期非创伤性股骨头坏死的组织功能恢复。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案，下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示实施例7动物造模后股骨头 X 线表现；
图2示实施例7模型动物治疗后第2周股骨头 X 线表现；
图3示实施例7模型动物治疗后第4周股骨头 X 线表现；
图4示实施例7模型动物治疗后第6周股骨头 X 线表现。
图5示手术中复合脱细胞基质注射液具体使用部位。
具体实施方式
下面结合本发明的具体实施例对本发明做进一步说明。
实施例1、复合脱细胞基质注射液的制备方法
脱细胞基质液的制备方法：（1）首先称取500g猪跟腱组织，用PBS对其进行清洗等预处理，经病毒灭活后粉碎；（2）加入2L 10%的氯化钠溶液浸泡摇床震荡处理2h，30℃/200rpm；（3）过滤，将组织用大量纯化水清洗3次，30min/次，摇床震荡处理10min，30℃/200rpm；（4）用2L 3%碳酸钠溶液浸泡3小时脱脂，纯化水洗3次：10min/次，30℃/200rpm；（5）用5L 4%胰蛋白酶浸泡摇床3小时，纯化水洗3次：10min/次，30℃/200rpm；（6）再经核酸酶降解细胞中核酸成分，充分清洗以除去去垢剂后得到脱细胞基质，经冻干后得到脱细胞基质粉；（7）配制pH=2 HCl溶液、10×PBS溶液、1×PBS溶液、0.1mol/L NaOH溶液；（8）按照1g基质粉/100mlHCl溶液/0.1g胃蛋白酶的比例进行酶解，酶解条件：200rpm/min、30℃、36h；（9）36h后酶解液中加入按1g基质液/0.05g胃蛋白酶的比例进行二次酶解，酶解条件：200rpm/min、30℃、36h；（10）过滤，除去未酶解基质；（11）酶提取液中加入氯化钠固体颗粒至浓度为 4mol/L，4℃下盐析 36 h；（12）盐析后过滤分离，沉淀用5倍量的3%的醋酸溶液溶解，然后再次盐析，纯化水冲洗沉淀数次，冻干；（13）按照1g冻干粉/100ml pH=2 HCl溶液的比例将冻干粉进行复溶；（14）按照12ml基质溶液加1.3ml 10×PBS加1.2ml 0.1mol/L NaOH溶液加5.5ml 1×PBS的比例在低温下混合，调节pH pH=7.3～7.5；（15）过滤除菌后装入无菌注射器中，2℃-8℃低温保存。
骨髓间充质干细胞的提取及培养方法：BMSCs提取过程在层流无菌手术室进行，对患者进行局部麻醉后，选取患者双侧髂后上棘部位进行穿刺，用含有肝素抗凝液的注射器抽取骨髓血200ml，将抽取的骨髓血打入医用无菌采血袋中；在无菌条件下，将采集袋中的自体骨髓血平均装入6个50ml离心管中，在2000r/min的转速下离心20min；离心完成后，去除离心管上层血浆，再用生理盐水稀释至30ml，并混合摇匀；将分离稀释后的骨髓细胞与20mlFicoll分离液，混合摇匀，1800r/min的转速下离心20min；离心后，用移液器小心吸取上层血浆与Ficoll分离液之间的白膜层细胞，用30ml生理盐水稀释吸取液，混合摇匀，1600r/min的转速下离心14min；离心后，用移液器吸取底部细胞，放入新的离心管中，加30ml生理盐水稀释，混合摇匀，1400r/min的转速下离心12min；再次吸取底部细胞，加30ml生理盐水稀释，混合摇匀，1200r/min的转速下离心10min；收取细胞加入无血清培养基，37℃，5%CO2条件下培养扩增至第3-5代使用。
当归寄生注射液：取生成检验合格的当归寄生注射液，备用。
取上述复合脱细胞基质注射液中组成成分脱细胞基质液1份、骨髓间充质干细胞液1份和当归寄生注射液1份，按照比例在手术时进行混合，装入10ml注射器中，复合为可注射的混合物。
实施例2、取实施例1中的复合脱细胞基质注射液中组成成分脱细胞基质液1.2份、骨髓间充质干细胞液1份和当归寄生注射液0.8份，按照比例在手术时进行混合，装入10ml注射器中，复合为可注射的混合物。
实施例3、取实施例1中的复合脱细胞基质注射液中组成成分脱细胞基质液0.8份、骨髓间充质干细胞液1份和当归寄生注射液1.2份，按照比例在手术时进行混合，装入10ml注射器中，复合为可注射的混合物。
实施例4、取实施例1中的复合脱细胞基质注射液中组成成分脱细胞基质液1份、骨髓间充质干细胞液1.2份和当归寄生注射液0.8份，按照比例在手术时进行混合，装入10ml注射器中，复合为可注射的混合物。
实施例5、将按比例混合后的可注射复合脱细胞基质液（1.2份脱细胞基质溶胶、1份骨髓间充质干细胞（细胞密度1×106～107个/ml，细胞活率>90%）及0.8份当归寄生注射液）于术中注入股骨头与髋臼之间髋关节部位，注射液复温条件为28℃，2min，复温后在3min内完全注射入体内。
实施例6、将按比例混合后的可注射复合脱细胞基质液（1.2份脱细胞基质溶胶、1份骨髓间充质干细胞（细胞密度1×106～107个/ml，细胞活率>90%）及0.8份当归寄生注射液）于术中注入股骨头与髋臼之间髋关节部位，注射液复温条件为35℃，2min，复温后在3min内完全注射入体内。
实施例7、有效性动物验证实验
实验方法：实验动物为普通级1月龄大白鼠，体重约280g，雌雄不限，共12只，6只左腿经过骨缘注射无水酒精，另6只左腿经过骨缘注射地塞米松造模2周。之后进行手术治疗，先用水合氯醛腹腔麻醉大白鼠，麻醉成功后将大白鼠俯卧位固定于手术台，剪除鼠毛，用安尔碘消毒左髋部3次，将复合脱细胞基质注射液0.5ml(0.1ml/min)缓慢注射至股骨头关节腔内。手术前肌肉注射苄星青霉素12万单位预防感染。术后在25℃空调房间里观察一天，第二天放回笼养。第1-3天观察2次/日，记录食量、精神状态和跛行程度。
主要观察：CT检查：实验动物分别在第2周，4周，6周行CT X 射线片检查，以水合氯醛腹腔麻醉后，双侧后肢八字形分开伸直，摄双侧髋关节正位片。
结果：第2周（图2），4周（图3）股骨头内骨坏死面积逐渐缩小，第6周（图4）股骨头骨密度均匀一致。
讨论：本动物实验通过研究复合脱细胞基质注射液，在股骨头坏死动物模型使用该生物复合材料诱导骨损伤区域血管再生及干细胞分化为成骨细胞，从而促进骨再生。该生物复合材料可提供力学稳定性和生物相容性，可模拟组织再生的最佳微环境，既可以保持病灶局部的干细胞浓度，也可诱导组织生长和组织再生特异性基因的活性信号表达，由于其骨诱导活性作为骨代用品。可注射的组织工程化干细胞复合脱细胞基质凝胶为早中期股骨头坏死提供了新的治疗方法。
Claims (5)
1.权利要求1：一种用于治疗股骨头坏死的复合脱细胞基质注射液，其特征在于，所述复合脱细胞基质注射液由异种哺乳动物组织经脱细胞处理得到的基质溶胶、骨髓间充质干细胞及当归寄生液复合而成，所述复合脱细胞基质注射液中组成成分的体积份为脱细胞基质溶胶0.8-1.2份、骨髓间充质干细胞液（细胞密度1×106～107个/ml，细胞活率>90%）0.8-1.2份和当归寄生注射液0.8-1.2份。
2.根据权利要求1所述的复合脱细胞基质注射液，其特征在于25℃-37℃条件下，随着时间增加，体系粘弹性增加，转化为半流动态，从纯粘性液体转变成粘弹性水凝胶，在体内可形成组织修复支架，提供有利于干细胞生长分化及组织再生的微环境。
3.根据权利要求1所述异种哺乳动物组织经脱细胞处理得到的基质溶胶，其特征在于，所述异种动物组织选自猪、牛、羊的心包膜、小肠粘膜下层、真皮、腹膜、韧带、跟腱、周围神经组织等。
4.一种脱细胞基质液的制备方法，其特征在于包括以下步骤：
（1）首先用PBS对动物组织进行清洗等预处理，经病毒灭活后粉碎；
（2）加入10%的氯化钠溶液浸泡摇床震荡处理2h，30℃/200rpm；
（3）过滤，将组织用纯化水清洗3次，30min/次，摇床震荡处理10min，30℃/200rpm；
（4）用3%碳酸钠溶液浸泡3小时脱脂，纯化水洗3次：10min/次，30℃/200rpm；
（5）用4%胰蛋白酶浸泡摇床3小时，纯化水洗3次：10min/次，30℃/200rpm；
（6）再经核酸酶降解细胞中核酸成分，充分清洗以除去去垢剂后得到脱细胞基质，经冻干后得到脱细胞基质粉；
（7）配制pH=2 HCl溶液、10×PBS溶液、1×PBS溶液、0.1mol/L NaOH溶液；
（8）按照1g基质粉/100ml HCl溶液/0.1g胃蛋白酶的比例进行酶解，酶解条件：200rpm/min、30℃、36h；
（9）36h后酶解液中加入按1g基质液/0.05g胃蛋白酶的比例进行二次酶解，酶解条件：200rpm/min、30℃、36h；
（10）过滤，除去未酶解基质；
（11）酶提取液中加入氯化钠固体颗粒至浓度为 4mol/L，4℃下盐析 36 h；
（12）盐析后过滤分离，沉淀用5倍量的3%的醋酸溶液溶解，然后再次盐析，纯化水冲洗沉淀数次，冻干；
（13）按照1g冻干粉/100ml pH=2 HCl溶液的比例将冻干粉进行复溶；
（14）按照12ml基质溶液加1.3ml 10×PBS加1.2ml 0.1mol/L NaOH溶液加5.5ml 1×PBS的比例在低温下混合，调节pH pH=7.3～7.5；
（15）过滤除菌后装入无菌注射器中，2℃-8℃低温保存。
5.一种用于治疗股骨头坏死的复合脱细胞基质注射液的使用方法：将按比例混合后的可注射复合脱细胞基质液（0.8-1.2份脱细胞基质溶胶、0.8-1.2份骨髓间充质干细胞（细胞密度1×106～107个/ml，细胞活率>90%）及0.8-1.2份当归寄生注射液）于术中注入股骨头与髋臼之间髋关节部位，注射液复温条件为25℃-37℃，1-2min，复温后需在3min内完全注射入体内。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010293104.1A CN111407785B (zh) | 2020-04-15 | 2020-04-15 | 一种用于治疗股骨头坏死的复合脱细胞基质注射液及使用方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010293104.1A CN111407785B (zh) | 2020-04-15 | 2020-04-15 | 一种用于治疗股骨头坏死的复合脱细胞基质注射液及使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111407785A true CN111407785A (zh) | 2020-07-14 |
| CN111407785B CN111407785B (zh) | 2022-04-15 |
Family
ID=71486497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010293104.1A Active CN111407785B (zh) | 2020-04-15 | 2020-04-15 | 一种用于治疗股骨头坏死的复合脱细胞基质注射液及使用方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111407785B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306749A (zh) * | 2022-01-06 | 2022-04-12 | 杭州倍荣生物科技有限公司 | 一种负载活细胞的胎盘脱细胞基质凝胶的制备及应用 |
| CN116492508A (zh) * | 2023-02-28 | 2023-07-28 | 诺一迈尔（苏州）医学科技有限公司 | 一种促进关节软骨修复的可注射水凝胶及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232970A (zh) * | 2010-04-22 | 2011-11-09 | 董运海 | 一种治疗骨损伤细胞注射剂及其制备方法 |
| CN104971380A (zh) * | 2014-04-11 | 2015-10-14 | 烟台隽秀生物科技有限公司 | 一种脱细胞基质修复凝胶及其制备新方法 |
| CN107929726A (zh) * | 2017-11-23 | 2018-04-20 | 吉林省拓华生物科技有限公司 | 一种干细胞复方注射液及其在制备防治股骨头坏死药物中的应用 |
| CN110237303A (zh) * | 2019-06-27 | 2019-09-17 | 浙江大学医学院附属邵逸夫医院 | 天然组织来源的脱细胞骨膜基质凝胶材料的制备方法 |
-
2020
- 2020-04-15 CN CN202010293104.1A patent/CN111407785B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102232970A (zh) * | 2010-04-22 | 2011-11-09 | 董运海 | 一种治疗骨损伤细胞注射剂及其制备方法 |
| CN104971380A (zh) * | 2014-04-11 | 2015-10-14 | 烟台隽秀生物科技有限公司 | 一种脱细胞基质修复凝胶及其制备新方法 |
| CN107929726A (zh) * | 2017-11-23 | 2018-04-20 | 吉林省拓华生物科技有限公司 | 一种干细胞复方注射液及其在制备防治股骨头坏死药物中的应用 |
| CN110237303A (zh) * | 2019-06-27 | 2019-09-17 | 浙江大学医学院附属邵逸夫医院 | 天然组织来源的脱细胞骨膜基质凝胶材料的制备方法 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306749A (zh) * | 2022-01-06 | 2022-04-12 | 杭州倍荣生物科技有限公司 | 一种负载活细胞的胎盘脱细胞基质凝胶的制备及应用 |
| CN116492508A (zh) * | 2023-02-28 | 2023-07-28 | 诺一迈尔（苏州）医学科技有限公司 | 一种促进关节软骨修复的可注射水凝胶及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111407785B (zh) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | 3D-bioprinted BMSC-laden biomimetic multiphasic scaffolds for efficient repair of osteochondral defects in an osteoarthritic rat model | |
| JP6123018B2 (ja) | 胎盤物質由来の製剤並びにその製造方法及び使用方法 | |
| JP2014520844A (ja) | コラーゲン、ヒアルロン酸誘導体及び哺乳類の臍帯由来幹細胞を含む軟骨細胞治療剤 | |
| RU2531046C2 (ru) | Быстрое получение и применение искусственных тканей и каркасов в качестве индивидуальных имплантатов | |
| CN111849882A (zh) | 间充质干细胞外泌体及其制备方法和应用 | |
| KR101121154B1 (ko) | 지방줄기세포 또는 지방세포를 포함한 이식용 조성물 | |
| Griffin et al. | The use of adipose stem cells in cranial facial surgery | |
| CN108865986B (zh) | 用于修复关节软骨损伤/缺损的间充质干细胞制剂及其制备方法和应用 | |
| CN111407785B (zh) | 一种用于治疗股骨头坏死的复合脱细胞基质注射液及使用方法 | |
| JP7230219B2 (ja) | 滑液膜由来の間葉系幹細胞及びその用途 | |
| CN106421917A (zh) | 制备用于软骨损伤修复的组合物的方法 | |
| TWI823964B (zh) | 幹細胞濾液製劑及其調製方法 | |
| CN106474156A (zh) | 组合物在制备药物中的用途 | |
| CN111297901B (zh) | 一种自体脂肪胶及其来源的间充质干细胞的制备方法及用途 | |
| JP2020097628A (ja) | 向上した多能性細胞及び微小血管組織ならびにその使用方法 | |
| CN104740613B (zh) | 脂联素在制备治疗骨折的药物中的应用 | |
| Levingstone et al. | Evaluation of a co-culture of rapidly isolated chondrocytes and stem cells seeded on tri-layered collagen-based scaffolds in a caprine osteochondral defect model | |
| CN106552288A (zh) | 制备软骨细胞组合物的方法 | |
| RU2461621C1 (ru) | Способ стимуляции формирования фиброзно-хрящевого регенерата костной мозоли у млекопитающих | |
| Zhong et al. | Advances focusing on the application of decellularization methods in tendon-bone healing | |
| CN1565643A (zh) | 一种基于骨髓间充质干细胞的组织工程化软骨 | |
| Sundaram et al. | Tissue engineering and regenerative medicine | |
| CN109876195B (zh) | 一种可诱导快速成骨的骨填充材料的制备方法 | |
| KR20140049772A (ko) | 근골격계 질환의 예방 또는 치료용 조성물 | |
| CN106540326A (zh) | 软骨细胞组合物在制备药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 7 Gao'an Street, Economic and Technological Development Zone, Yantai City, Shandong Province, 265599 Patentee after: SHANDONG JUNXIU BIOTECHNOLOGY CO.,LTD. Address before: 264006 room 539, No. 3 plant, overseas students entrepreneurship Park, No. 32, Zhujiang Road, Yantai Economic and Technological Development Zone, Shandong Province Patentee before: SHANDONG JUNXIU BIOTECHNOLOGY CO.,LTD. |